Some studies in T2D note small initial increases in RAS after acute SGLT2 inhibition (Puglisi et al., 2021), but the chronic RAS responses to SGLT2 inhibition have not been thoroughly investigated. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.